|
|
 |
|
Viewing report
|
|
|
|
Cytos Biotechnology AG Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Merchant Research and Consulting Ltd, July 2011, Pages: 71
Cytos Biotechnology AG Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Cytos Biotechnology AG and its competitors. This provides our Clients with a clear understanding of Cytos Biotechnology AG position in the Pharmaceuticals and Biotechnology Industry.
Scope
The report contains the company’s profile and data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
The SWOT-analysis provides information about the company’s strengths, weaknesses, opportunities, and possible threats against it.
The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency.
It also shows the company’s income statement and ratio trend-charts, with balance sheets and cash flows presented on an annual and quarterly basis.
Company’s financial ratios are directly compared with those of its competitors through industry averages.
The report provides relevant news, an analysis of PR-activity, and stock price movements.
The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms.
The benefits of buying the Report are as follows:
Readers will gain an unrivalled in-depth knowledge about the company.
The report will help the management of your business environment. This will be achieved through the report’s unique analysis of both the market and company’s competitors, and by providing detailed information about the internal and external factors that affect the relevant industry.
Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
The report will help you to find prospective partners and suppliers.
The annual profitability data provided in the report will assist and strengthen your company’s decision-making processes.
About Cytos Biotechnology AG
Cytos Biotechnology AG, a biotechnology company, together with its subsidiaries, engages in the discovery, development, and commercialization of biopharmaceutical products for the prevention and treatment of chronic diseases in Switzerland and the United States. It develops a class of biopharmaceutical products known as Immunodrugs that are designed to instruct the patient?s immune system to produce desired antibody or T-cell responses able to interfere with and modify common chronic disease processes. The company?s lead product candidate, NIC002, is in Phase II clinical development for the treatment of nicotine addiction. Its products also include CYT006-AngQb, a therapeutic vaccine under Phase IIa clinical trial for the treatment of hypertension; CYT003-QbG10, a novel immunotherapy under Phase II trial for the treatment of allergy and asthma; and CYT004-MelQbG10, which is under Phase IIa clinical trial for the treatment of malignant melanoma. The company is also partnering with Novartis to develop CAD106, a Phase IIa clinical trial product for the treatment of Alzheimer?s disease; and developing CYT013-IL1bQb, a Phase I/IIa clinical trial product for the treatment of type II diabetes. Cytos Biotechnology AG has a collaboration agreement with Agency for Science, Technology and Research for research, development, and commercialization of a VLP vaccine to manage influenza infections. Cytos Biotechnology AG is based in Schlieren, Switzerland.
|
|
|
|
